Document:

EX-10.9.2

 Exhibit 10.9.2 

CONFIDENTIAL TREATMENT REQUESTED. INFORMATION FOR WHICH CONFIDENTIAL TREATMENT HAS BEEN REQUESTED IS OMITTED AND MARKED WITH “[***]”. AN
UNREDACTED VERSION OF THE DOCUMENT HAS ALSO BEEN FURNISHED SEPARATELY TO THE SECURITIES AND EXCHANGE COMMISSION AS REQUIRED BY RULE 406 UNDER THE SECURITIES ACT OF 1933, AS AMENDED. 

 
  

ATTACHMENT A 
 PROJECT
RIDER #3 
 This Rider #3 (“Rider”) is issued pursuant to the Collaboration Agreement (“Agreement”), effective
November 10,2017, between Magenta Therapeutics (“Magenta”) and Be The Match BioTherapies, LLC (“BTMB”) and incorporates all of the terms and conditions therein. The effective date of this Rider shall be the
date of the final signature executing this Rider. 
 POINT OF CONTACT 

Be The Match BioTherapies - 500 N 5th St.. Minneapolis. MN 55401 

	 	•	 	 Contact: [***] 

	 	•	 	 Phone:   [***] 

	 	•	 	 E-mail:  [***] 

Magenta Therapeutics -100 Technology Square. 5th Fl. Cambridge. MA
02139 

	 	•	 	 Contact: [***] 

	 	•	 	 Phone:   [***] 

	 	•	 	 E-mail:  [***] 

BTMB and Magenta (each a “Party” and collectively the “Parties”) agree as follows: 

 

	A.	 STATEMENT OF WORK. 

BTMB will provide the following services: 

Process Development 

Develop and document the procedures and training required to implement services for Magenta’s study. This will include one information
session delivered via WebEx for each clinical site. Information sessions will include a presentation of the visual aide that BTMB will create and a brief review of the Magenta project. 

Search Strategy Assistance 

BTMB will assist transplant centers (“TC” or “TCs”) when requested to help determine available cord blood unit(s)
(“CBU” or “CBUs”) that best meet Magenta-defined criteria for CBU attributes. BTMB will also provide consultation regarding other cord blood product related questions that may arise from the TCs. 

Case Management 
 BTMB
will provide designated Case Manager(s) (“CM” or CMs”) to assist in end to end management of CBU requests and cases. The TCs and BTMB will use currently available technology to assist in the ordering and logistics of the CBUs from the
cord blood banks to Magenta’s identified manufacturing facility. BTMB will provide Magenta and the manufacturer(s) with required updates outside of the current available technology. BTMB 

  
 Page 1 of 4 

Services Agreement 

 CONFIDENTIAL TREATMENT REQUESTED. INFORMATION FOR WHICH CONFIDENTIAL TREATMENT HAS BEEN REQUESTED IS
OMITTED AND MARKED WITH “[***]”. AN UNREDACTED VERSION OF THE DOCUMENT HAS ALSO BEEN FURNISHED SEPARATELY TO THE SECURITIES AND EXCHANGE COMMISSION AS REQUIRED BY RULE 406 UNDER THE SECURITIES ACT OF 1933, AS AMENDED. 

 

 
will also coordinate delivery of a charged dry shipper to Magenta’s identified manufacturing facility prior to the second phase of shipment of the manufactured therapy to the TC, schedule
and manage shipment of the manufactured therapy to the TC and return of the empty dry shipper, and provide logistics support for all phases of shipment (the “Product Logistics”). 

Supply Chain Logistics 

BTMB will utilize mutually agreeable service provider(s) for the shipment of the CBU and final product and ensure that all required regulations
are met. 
  

	B.	 PROJECT CHANGES. 

The Parties understand that in order to reflect changes to this Rider, the Rider will be subject to amendment by the Parties. Each party’s
respective Point Of Contact identified above may request or submit a written request for change to the other party’s Point of Contact. The request for change should describe in appropriate detail the nature, extent and proposed manner of
performance of the proposed change, related implications (if any) arising there from and estimated scheduling, pricing and cost information relating thereto. Written approval or rejection of the requested change will be provided within [***] from
the date of receipt. 
  

	C.	 COMPENSATION OF BTMB. 

BTMB shall be compensated in exchange for the provision of services in accordance with the terms of the Agreement in accordance with the
Payment Schedule set forth below. All amounts due under this Payment Schedule will be invoiced in United States Dollars as follows: 
  

	 	1.	 Payment Schedule 

 

	 	1.1	 Process Development 

Magenta agrees to pay BTMB upon execution of this Rider $[***] ([***] dollars) for activities related to the development of standard operating
procedures and BTMB staff training to support Magenta’s clinical study. Half ($[***]) of the fee will be billed upon contract execution and the other half ($[***]) will be invoiced upon the completion of the Process Development steps. 

 

	 	1.2	 Search Strategy 

Magenta agrees to pay BTMB $[***] ([***] dollars) for each Search Strategy Advice report requested by and delivered to a TC for a CBU that is
subsequently requested for Magenta manufacturing by aforementioned TC. 
  

	 	1.3	 Case Management 

Magenta agrees to pay BTMB $[***] ([***] dollars) for
end-to-end management of each patient’s CBU needs and Product Logistics. 

  
 Page 2 of 4 

Services Agreement 

 CONFIDENTIAL TREATMENT REQUESTED. INFORMATION FOR WHICH CONFIDENTIAL TREATMENT HAS BEEN REQUESTED IS
OMITTED AND MARKED WITH “[***]”. AN UNREDACTED VERSION OF THE DOCUMENT HAS ALSO BEEN FURNISHED SEPARATELY TO THE SECURITIES AND EXCHANGE COMMISSION AS REQUIRED BY RULE 406 UNDER THE SECURITIES ACT OF 1933, AS AMENDED. 

 

	 	1.4	 Logistics Costs 

Magenta agrees to pay all actual shipping fees (billed at cost) associated with the BTMB facilitation of the CBU from the manufacturer to the
TC. BTMB will not mark up these fees and work to secure the best possible pricing for Magenta while maintaining the needed compliance and chain of custody requirements. 
  

	 	2.	 Travel 

Any travel by BTMB personnel under this Rider shall be approved in writing in advance by Magenta. All travel and any reasonable expenses
associated with pre-approved travel will be reimbursed by Magenta in accordance with the applicable BTMB travel policies and procedures in effect at such time as the travel and/or travel expenses are incurred
by BTMB. BTMB will use its own designated travel agency to book pre-approved travel. Travel expenses incurred will be categorized as “Travel” on BTMB invoices and will be appropriately described.

  

	 	3.	 Invoice. 

BTMB may use its own invoice format referencing this Rider or Purchase Order assigned. All BTMB invoices shall be sent to the Magenta Point of
Contact provided at the address listed above or via email to Magenta Accounting at [***]. 
 On a monthly basis, BTMB will invoice Magenta
for CBUs delivered to TC during the prior month at a rate of $[***] for each unit and / or search strategy advice services provided at a rate of $[***] per instance. All duly issued invoices are due and payable within [***] from invoice date in
currency USD. Invoice number must be included with payment. 
 For automated clearing house (ACH) remit funds (free of all bank fees) to:

 [***] 
 Magenta is not
required to pay any amounts, costs or expenses, except as expressly set forth in this Section (C). 
  

	D.	 TERM. 

The term of this Rider shall commence on the Rider effective date set forth above and continue and remain in effect through [***] from the
Rider effective date. 
  

	E.	 TERMINATION OF RIDER. 

Upon the effective date of any termination, BTMB shall immediately cease performance of its Services. Magenta agrees to pay BTMB for all
services performed through the effective date of termination. 
 This Rider must be signed by individuals authorized to legally bind their
respective Parties. 

  
 Page 3 of 4 

Services Agreement 

 CONFIDENTIAL TREATMENT REQUESTED. INFORMATION FOR WHICH CONFIDENTIAL TREATMENT HAS BEEN REQUESTED IS
OMITTED AND MARKED WITH “[***]”. AN UNREDACTED VERSION OF THE DOCUMENT HAS ALSO BEEN FURNISHED SEPARATELY TO THE SECURITIES AND EXCHANGE COMMISSION AS REQUIRED BY RULE 406 UNDER THE SECURITIES ACT OF 1933, AS AMENDED. 

 

									
	BE THE MATCH BIOTHERAPIES, LLC	 		 	MAGENTA THERAPEUTICS
					
	By:	 	/s/ Brian Lindberg	 		 	By:	 	/s/ Karen M. Nichols
		 	Authorized Signature	 		 		 	Authorized Signature
					
		 	Brian Lindberg	 		 		 	Karen M. Nichols
		 	(Typed/Printed Name)	 		 		 	(Typed/Printed Name)
					
	Title:	 	Corporate Vice President	 		 	Title:	 	VP, Regulatory and Quality
					
	Date:	 	Sep 6, 2018	 		 	Date:	 	30 Aug 2018

  
 Page 4 of 4 

Services AgreementEX-10.9.3

 Exhibit 10.9.3 

AMENDMENT #1 
 TO

 PROJECT RIDER #1 

COLLABORATION AGREEMENT 
 This Amendment
#1 (“Amendment #1”) is entered into effective as of the date of the final signature executing this Amendment #1 (“Amendment #1 Effective Date”), by and between Magenta Therapeutics, Inc.
(“Magenta”) and Be The Match Biotherapies, LLC (“BTMB”), (each a “Party” and collectively the “Parties”) as those Parties are defined in Attachment
A, Project Rider, effective December 6, 2017 (collectively, the “Project Rider #1”). 
 WHEREAS, the Parties executed a Collaboration
Agreement, effective November 10, 2017, and Project Rider #1, effective December 6, 2017; and 
 WHEREAS, the Parties agree to revise the
Statement of Work and Payment Schedule of the Project Rider #1. 
 NOW, THEREFORE, for the valuable consideration contained herein, and intending to be
legally bound, Magenta and BTMB agree to the following amendments to be effective as of the Amendment #1 Effective Date as follows: 
 Amendment to Project
Rider #1 
  

	 	1.	 Revise subparagraph (a) of Section A. Statement of Work so that Dr. Dennis Confer is replaced
with Dr. Steven Devine. 

  

	 	2.	 Delete the Payment Schedule in Section D. Compensation of BTMB of Project Rider #1 in its
entirety and replace it with the following to read as follows: 

 PAYMENT SCHEDULE 

 

			
	$248,804 for Services provided by BTMB during the December 6, 2017 through December 31, 2018 timeperiod.	  	The Parties have mutually agreed that the total amount due BTMB for the December 6, 2017 through December 31, 2018 timeperiod has been
revised to a fixed price payment of $248,804, of which BTMB has already received payment in full.
	 	 
	 	  	The Parties also acknowledge that the CIBMTR Corporate Leader Level membership for 2018 (as referenced in subparagraph (c) of Section A.
Statement of Work) has been paid in full.

  
 1 

			
	 	  	 
	For Services provided by BTMB during Calendar Year 2019 (January 1, 2019 through December 31, 2019), Magenta will pay BTMB a fixed price quarterly payment of $25,000.	  	BTMB will invoice $25,000 every January 15th for consulting services occurring during the period commencing January 1st and ending March 3lst.
	 	 
	 	  	BTMB will invoice $25,000 every April 15th for consulting services commencing April 1st and ending June 30th.
	 	 
	 	  	BTMB will invoice $25,000 every July 15th for consulting services commencing July 1st and ending September 30th.
	 	 
	 	  	BTMB will invoice $25,000 every October 15th for consulting services commencing October
1st and ending December 31st.

 [Remainder of page intentionally left blank.] 

  
 2 

 This Amendment #1 is executed by individuals who are duly authorized to legally bind their respective
parties as of the Amendment #1 Effective Date: 
  

									
	MAGENTA THERAPEUTICS, INC.	 	    BE THE MATCH BIOTHERAPIES, LLC
					
	By:	 	 /s/ Christina Isacson
	 		 	By:	 	 /s/ Brian Lindberg

		 	Authorized Signature	 		 		 	Authorized Signature
					
		 	 Christina Isacson
	 		 		 	 Brian Lindberg

		 	  (Typed/Printed Name)	 		 		 	  (Typed/Printed Name)
					
	 Title:
	 	 CBO
	 		 	 Title:
	 	 Corporate Vice President

					
	 Date:
	 	 12/6/18
	 		 	 Date:
	 	 Dec 6, 2018

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00293-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00293-of-00352.parquet"}]]